Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2/3 1Phase 2 1

Status

Unknown 3Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 2OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 6

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Colorectal Neoplasms 19Carcinoma, Hepatocellular 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Sarcoma 6Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Nasopharyngeal Neoplasms 4

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumor × spartalizumab × Clear all
NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase 1/2 Recruiting
183 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03874897 2024-04-30

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Peking University

Phase 1 Completed
134 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05204862 2023-04-03

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

TiumBio Co., Ltd.

Phase 1/2 Recruiting
240 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03704246 2021-03-04

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Taizhou Hanzhong biomedical co. LTD

Phase 2 Unknown
123 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04478461 2020-11-13

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1 Unknown
21 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡